Semaglutide studies: 1,194 papers with results
Page 14 of 24
- Adding Semaglutide to SGLT2 Inhibitors Reduces Liver Enzymes in Patients with Type 2 Diabetes Complicated by Metabolic Dysfunction Associated Steatotic Liver Disease: A Retrospective Observational Study.
Sato K · Internal medicine (Tokyo, Japan) · 2026
Observational study · 8 results
- Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study.
Lago Garma J · Endocrinologia, diabetes y nutricion · 2026
Observational study · 5 results
- Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study.
Jensen AB · BMC endocrine disorders · 2025
Observational study · 12 results
- Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity.
Ferrulli A · Obesity (Silver Spring, Md.) · 2026
Observational study · 4 results
- Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study.
Takashima S · Diabetology international · 2026
Observational study · 7 results
- The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study.
Jensterle M · Frontiers in endocrinology · 2024
Observational study · 8 results
- The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population.
Petrakis V · Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2026
Observational study · 12 results
- Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice.
Sawada M · Endocrinology, diabetes & metabolism · 2026
Observational study · 11 results
- Patients With Severe Obesity Are Made Eligible for Complex Abdominal Wall Repair After Preoptimization With GLP-1 Agonists: Results of a Bicentric Pilot Study.
Romain B · World journal of surgery · 2025
Observational study · 10 results
- Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.
Takahara M · Internal medicine (Tokyo, Japan) · 2024
Observational study · 5 results
- Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Wei Y · Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026
Observational study · 4 results
- Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study.
Kakegawa T · Medicine · 2024
Observational study · 12 results
- Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.
Sherwin M · Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2023
Observational study · 4 results
- Effects of semaglutide, a GLP-1 receptor agonist, on food preferences in Japanese subjects with type 2 diabetes and visceral fat accumulation.
Hara T · Endocrine journal · 2026
Observational study · 10 results
- Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome.
Ahmed S · Frontiers in endocrinology · 2026
Observational study · 6 results
- Semaglutide-associated kidney injury.
Begum F · Clinical kidney journal · 2024
Observational study · 5 results
- Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.
Gras C · European journal of clinical nutrition · 2025
Observational study · 6 results
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.
Cai CX · JAMA ophthalmology · 2025
Observational study · 6 results
- Proteomic changes upon treatment with semaglutide in individuals with obesity.
Maretty L · Nature medicine · 2025
Observational study · 3 results
- Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
Chiappini S · Pharmaceuticals (Basel, Switzerland) · 2023
Observational study · 7 results
- Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
Uzoigwe C · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
Observational study · 15 results
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®).
McIntyre RS · Journal of affective disorders · 2025
Observational study · 13 results
- Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
Lingvay I · BMJ open diabetes research & care · 2020
Observational study · 7 results
- Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.
Lakhani M · American journal of ophthalmology · 2025
Observational study · 12 results
- Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.
He L · Frontiers in pharmacology · 2024
Observational study · 17 results
- Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
Krüger N · Nature medicine · 2026
Observational study · 5 results
- Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.
Mody R · Clinical therapeutics · 2022
Observational study · 9 results
- Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes.
Chaiyakunapruk N · Cardiovascular diabetology · 2025
Observational study · 7 results
- Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.
Guo H · Frontiers in pharmacology · 2024
Observational study · 12 results
- Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
Stottlemyer BA · Therapeutic advances in drug safety · 2023
Observational study · 2 results
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.
Nakhla M · Cardiovascular drugs and therapy · 2025
Observational study · 20 results
- Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
Vilsbøll T · Diabetes, obesity & metabolism · 2023
Observational study · 4 results
- Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.
Horii T · Journal of diabetes investigation · 2024
Observational study · 3 results
- Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system.
Huang H · British journal of anaesthesia · 2025
Observational study · 10 results
- The impact of approved anti-obesity medications on osteoarthritis.
Baser O · Expert opinion on pharmacotherapy · 2024
Observational study · 7 results
- Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
Shirani A · Therapeutic advances in neurological disorders · 2024
Observational study · 3 results
- Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting.
Lv L · Primary care diabetes · 2024
Observational study · 3 results
- Otolaryngologic Side Effects of GLP-1 Receptor Agonists.
Khan FI · The Laryngoscope · 2025
Observational study · 20 results
- GLP-1 Agonists in Aesthetic Surgery: Implications for Perioperative Outcomes and Body Contouring Procedures.
Albanese R · Aesthetic plastic surgery · 2025
Observational study · 3 results
- Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.
Butt MI · Annals of Saudi medicine · 2024
Observational study · 7 results
- Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.
Ipaye T · Diabetes, obesity & metabolism · 2025
Observational study · 6 results
- Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy.
Bahdi F · Clinical obesity · 2025
Observational study · 21 results
- GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.
Pak KY · Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2025
Observational study · 36 results
- Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study.
Chen SY · European heart journal. Cardiovascular pharmacotherapy · 2025
Observational study · 28 results
- A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.
Rahbek MT · Pharmacoepidemiology and drug safety · 2024
Observational study · 6 results
- Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.
von Arx LB · Diabetes, obesity & metabolism · 2023
Observational study · 6 results
- Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status.
Ulrich FS · Diabetes, obesity & metabolism · 2026
Observational study · 18 results
- One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.
Donnelly LA · Diabetes, obesity & metabolism · 2026
Observational study · 14 results
- Semaglutide and diabetic retinopathy: an OHDSI network study.
Cai CX · BMJ open diabetes research & care · 2025
Observational study · 10 results
- Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
Overgaard RV · Diabetes, obesity & metabolism · 2026
Observational study · 3 results